Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02281474 · ClinicalTrials.gov registry record · Phase 1
Nilotinib in Cognitively Impaired Parkinson Disease Patients 001
A Phase 1 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02281474 is a Phase 1 study that has completed, run by Georgetown University. The registered enrollment target is 12 participants.
The verdict
NCT02281474, a Phase 1 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This pilot study will test Nilotinib's ability to alter the abnormal protein build up in Parkinson disease and Diffuse Lewey Body Disease patients . Patients will receive Nilotinib at different doses for 6 months. Patients will then be tested to see if there is change in three areas: 1) has the disease symptoms changed. 2) has levels of a specific misfolded protein changed in the fluid around their brain and spine. 3) Have inflammatory markers changed in the patient's blood and fluid around their brain and spine. If successful, this drug could be used to slow down or stop the progression of disorders that involve abnormal collection of misfolded proteins. However, the main purpose of this pilot study is to check for the safety of using this medication at this level.
Interventions
- DRUG Nilotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02281474
The ClinicalTrials.gov registry entry for NCT02281474 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nilotinib is the first listed.
NCT02281474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02281474 about?
NCT02281474 is a clinical study titled "Nilotinib in Cognitively Impaired Parkinson Disease Patients 001". This pilot study will test Nilotinib's ability to alter the abnormal protein build up in Parkinson disease and Diffuse Lewey Body Disease patients . Patients will receive Nilotinib at different doses for 6 months. Patients will then be tested to see if there is change in three areas: 1) has the dise...
What is the current status of trial NCT02281474?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-11.
What interventions are being tested in trial NCT02281474?
The interventions under investigation include: Nilotinib (DRUG).
Who is sponsoring clinical trial NCT02281474?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.